| 前收市價 | 39.07 |
| 開市 | 39.63 |
| 買盤 | 39.72 x 2200 |
| 賣出價 | 40.00 x 800 |
| 今日波幅 | 39.59 - 40.12 |
| 52 週波幅 | 33.67 - 45.93 |
| 成交量 | |
| 平均成交量 | 3,615,818 |
| 市值 | 81.277B |
| Beta 值 (5 年，每月) | 0.30 |
| 市盈率 (最近 12 個月) | 14.19 |
| 每股盈利 (最近 12 個月) | 2.81 |
| 業績公佈日 | 2024年7月31日 |
| 遠期股息及收益率 | 1.49 (3.81%) |
| 除息日 | 2024年5月16日 |
| 1 年預測目標價 | 45.80 |
ZacksGSK (GSK) Earnings Expected to Grow: Should You Buy?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolIs GSK a Top Value Stock Right Now?
GSK, a multinational pharma company, scans as a bargain.
InvestorPlace3 Top Cancer Treatment Stocks to Buy Now
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck’s (NYSE:MRK) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year. And even back in 2018, its fourth year on the market, the drug was responsible for putting $7.2 billion in Merck’s coffers. Many new types of cancer treatments are being developed, including personalized cancer vaccines, and precision oncology treatments. But
